Pharmalife

Home
Pharmalife

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Pharmalife, Medical supply store, 2951 Piedmont Road NE, Ste. B, .

We currently operate 3 pharmacies with a focus on the Retail, Mail-Order, Long Term Care (Assisted Living / Nursing Home / Psychiatric Residential), and Correctional Facility marketplaces.

03/05/2023

PHARMACY BULLETIN - Bulletin - April 28th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-04-28-2023

Seres Therapeutics won approval from the U.S. Food and Drug Administration (FDA) on April 26, 2023, for Vowst™ (f***l microbiota spores, live-brpk) capsules. A biotherapeutic (treatment that contains living organisms), it is indicated for preventing subsequent reinfections with Clostridioides diff...

06/04/2023

PHARMACY BULLETIN - Bulletin - March 27th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners at Pharmalife: https://vativorx.com/pharmacy-bulletin-03-27-2023

On March 24, 2023, the Pharming Group received approval from the U.S. Food and Drug Administration (FDA) for Joenja® (leniolisib) tablets. It is the first drug indicated for the treatment of patients who have activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). Candidates for therapy...

28/03/2023

PHARMACY BULLETIN - Bulletin - March 24th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-03-24-2023

Regeneron received expanded approval from the U.S. Food and Drug Administration (FDA) on March 21, 2023, to widen the indication for Evkeeza™ (evinacumab-dgnb) injection to include children as young as five years old.

27/03/2023

PHARMACY BULLETIN - Bulletin - March 23rd, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-03-23-2023

Rezzayo™ (rezafungin) injection was approved by the U.S. Food and Drug Administration (FDA) on March 22, 2023.

24/03/2023

PHARMACY BULLETIN - Bulletin - March 22nd, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-03-22-2023

Zynyz™ (retifanlimab-dlwr - Incyte) injection received Accelerated Approval from the U.S. Food and Drug Administration (FDA) on March 22, 2023.

20/03/2023

PHARMACY BULLETIN - Bulletin - March 18th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-03-18-2023

The U.S. Food and Drug Administration (FDA) approved Zavzpret™ (zavegepant - Pfizer) Nasal Spray on March 9, 2023.

13/03/2023

PHARMACY BULLETIN - Bulletin - March 10th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-03-10-2023

The U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals’ Naloxone Nasal Spray, 4mg, on March 7, 2023. It was approved as a new formulation, not a generic because it has a patented delivery device.

20/02/2023

PHARMACY BULLETIN - Bulletin - February 20th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-02-20-2023

On Feb. 16, 2023, Chiesi Global Rare Diseases earned approval for Lamzede® (velmanase alfa-tycv) injection from the U.S. Food and Drug Administration (FDA). It treats the non-central nervous system (CNS) symptoms of an extremely rare progressive disease, alpha-mannosidosis.

17/02/2023

PHARMACY BULLETIN - Bulletin - February 17th, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-02-17-2023

Jemperli (dostarlimab-gxly - GSK) injection is a programmed cell death-1 (PD-1) inhibitor that received Accelerated Approval from the U.S. Food and Drug Administration (FDA) in April 2021.

07/02/2023

PHARMACY BULLETIN - Bulletin - February 3rd, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-02-03-2023

In a financial report released on Jan. 31, 2023, Pfizer disclosed that the indication for Ibrance® (palbociclib) has been extended. Pfizer’s cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is marketed in both oral capsules and tablets.

02/02/2023

PHARMACY BULLETIN - Bulletin - February 2nd, 2023

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read Bulletin from our partners VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-02-02-2023

The U.S. Food and Drug Administration (FDA) approved Jesduvroq (daprodustat – GSK) tablets on Feb. 1, 2023.

13/09/2022

PHARMACY BULLETIN - Bulletin #47

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Read bulletin from our partners at VativoRx, LLC: https://vativorx.com/pharmacy-bulletin-08-18-22/

On Aug. 17, 2022, the U.S. Food and Drug Administration (FDA) approved bluebird bio’s Zynteglo® (betibeglogene autotemcel, beti-cel). It’s a personalized stem cell-based gene therapy to treat adult and pediatric patients who have transfusion-dependent beta-thalassemia.

Address

2951 Piedmont Road NE, Ste. B

30305

Website

http://www.pharmalife.com/

Alerts

Be the first to know and let us send you an email when Pharmalife posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic?

Country:

City: